HB1628 group had lower DAIs, histology scores, and serum levels of pro-inflammatory cytokines (IL-1β and TNF-α), but higher levels of an anti-inflammatory cytokine (IL-13), compared with the DSS group, suggesting a less severe inflammatory state after the HB1628 intervention.
Peroral treatment with <i>L. reuteri</i> improved colitis severity clinically and morphologically and reduced the colonic levels of Tumor necrosis factor-α (TNF-α) (<i>Tnf</i>), Interleukin 1-β (<i>Il1β</i>), and nterferon-γ (<i>Ifng</i>)